KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Alnylam Pharmaceuticals (ALNY) Land & Improvements (2017 - 2018)

Alnylam Pharmaceuticals (ALNY) has disclosed Land & Improvements for 2 consecutive years, with $9.1 million as the latest value for Q4 2018.

For Q4 2018, Land & Improvements changed 0.0% year-over-year to $9.1 million; the TTM value through Dec 2018 reached $9.1 million, changed 0.0%, while the annual FY2018 figure was $9.1 million, 0.0% changed from the prior year.
Land & Improvements hit $9.1 million in Q4 2018 for Alnylam Pharmaceuticals, roughly flat from $9.1 million in the prior quarter.
Across five years, Land & Improvements topped out at $9.1 million in Q4 2017 and bottomed at $9.1 million in Q4 2017.